Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492 Siegel, 2018, Cancer statistics, 2018, CA Cancer J Clin, 68, 7, 10.3322/caac.21442 Dabestani, 2016, Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study, World J Urol, 34, 1081, 10.1007/s00345-016-1773-y Larcher, 2019, Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates?, Eur Urol Oncol, 2, 365, 10.1016/j.euo.2019.04.007 Hahn, 2019, First-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis, Eur Urol Oncol, 2, 708, 10.1016/j.euo.2019.09.002 de Velasco, 2019, Sequencing and combination of systemic therapy in metastatic renal cell carcinoma, Eur Urol Oncol, 2, 505, 10.1016/j.euo.2019.06.022 Motzer, 2002, Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology, J Clin Oncol, 20, 2376, 10.1200/JCO.2002.11.123 Heng, 2013, External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study, Lancet Oncol, 14, 141, 10.1016/S1470-2045(12)70559-4 Kroeger, 2013, Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria, Cancer, 119, 2999, 10.1002/cncr.28151 Connor Wells, 2017, Characterizing the outcomes of metastatic papillary renal cell carcinoma, Cancer Med, 6, 902, 10.1002/cam4.1048 Kammerer-Jacquet, 2017, Synchronous metastatic clear-cell renal cell carcinoma: a distinct morphologic, immunohistochemical, and molecular phenotype, Clin Genitourin Cancer, 15, e1, 10.1016/j.clgc.2016.06.007 Heng, 2009, Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study, J Clin Oncol, 27, 5794, 10.1200/JCO.2008.21.4809 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Escudier, 2007, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, Lancet, 370, 2103, 10.1016/S0140-6736(07)61904-7 Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838 Rini, 2008, Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206, J Clin Oncol, 26, 5422, 10.1200/JCO.2008.16.9847 Sternberg, 2010, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial, J Clin Oncol, 28, 1061, 10.1200/JCO.2009.23.9764 Motzer, 2013, Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N Engl J Med, 369, 722, 10.1056/NEJMoa1303989 Choueiri, 2017, Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial, J Clin Oncol, 35, 591, 10.1200/JCO.2016.70.7398 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126 Rini, 2019, Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial, Lancet, 393, 2404, 10.1016/S0140-6736(19)30723-8 Motzer, 2019, Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1103, 10.1056/NEJMoa1816047 Rini, 2019, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1116, 10.1056/NEJMoa1816714 Bex, 2019, Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial, JAMA Oncol, 5, 164, 10.1001/jamaoncol.2018.5543 Mejean, 2018, Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma, N Engl J Med, 379, 417, 10.1056/NEJMoa1803675 Mitchell, 2018, Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx Renal, Cell, 173, 611, 10.1016/j.cell.2018.02.020 Turajlic, 2018, Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal, Cell, 173, 595, 10.1016/j.cell.2018.03.043 Turajlic, 2018, Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal, Cell, 173, 581, 10.1016/j.cell.2018.03.057 Verbiest, 2019, Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors, Clin Genitourin Cancer, 17, e981, 10.1016/j.clgc.2019.05.009